Granules' ₹1,093 Cr warrant balance is paid — funded by a ₹1,509 Cr promoter share sale four days earlier
Dr. Krishna Prasad Chigurupati sold 1.72 crore shares on Sep 11; on Sep 15 the promoter group paid the balance 75% of its warrant subscription, making 2,49,14,530 warrants convertible.
₹872.60
Sep 15 · −4.0% on the day
LARGE-CAP
by market cap ≈ ₹21,623 Cr
₹1,093 Cr
the 75% balance · Sep 15
1.72 Cr
Sep 11 · ≈ ₹1,509 Cr
2,49,14,530
≈ 10.1% of current share count
₹922.95
set intraday on Sep 15
Two filings, four days apart, that the second filing itself connects
Promoter sells 1,72,00,000 shares through a block deal and the open market
The company informed the exchange that Dr. Krishna Prasad Chigurupati, Promoter, sold 1,72,00,000 equity shares on September 11 through a block deal and the open market, with participation the filing describes as marquee institutional investors — it names Capital Group, Kotak Mahindra Life Insurance Company, ChrysCapital and Allspring. The filing states the transaction was undertaken to fund the second tranche of the Company's ongoing preferential issue, and that the funds raised through the preferential issue in February 2026 were deployed significantly earlier than anticipated. The filing reached the exchange at 18:35 IST, after close.
Read:Exchange bulk/block disclosures the same day show the sale in two legs: 1,32,95,129 shares at ₹872.50 (≈ ₹1,160 crore) and 39,04,871 shares at ₹892.84 (≈ ₹348.6 crore) — about ₹1,508.6 crore in total. The stated purpose matters: this was a sale announced as the funding step for a payment into the company, not a standalone stake reduction.
Company update to BSE, Sep 11, 2026Promoter group pays the balance ₹1,093 crore; all 2,49,14,530 warrants fully paid
Further to its disclosures dated February 23, 2026 and September 11, 2026, the company informed the exchange that members of the promoter group have paid the balance 75% subscription amount of ₹1,093 crore towards the preferential issue. Following receipt, 2,49,14,530 warrants issued to the promoter-group investor category are fully paid and eligible for conversion into equity shares under the issue terms. The filing reached the exchange at 19:42 IST on September 15, after close.
Read:The filing states that upon receipt of the subscription amount the company will be in a net cash surplus position on a consolidated basis, and that the strengthened capital position lets it expedite the preferential issue objects and deploy growth capital ahead of the originally envisaged timelines. Because the filing landed after Tuesday's close, its first tradable session falls outside this report's price window — no market reaction can be attributed to it yet.
Company update to BSE, Sep 15, 2026Taken together, the two filings describe one funding chain: a promoter sold existing shares in the market on Friday, and by Tuesday evening the promoter group had paid the company the ₹1,093 crore balance on its warrant subscription. The company's own September 11 filing makes the link explicit — the sale "was undertaken to fund the second tranche of the Company's ongoing preferential issue." The money left the market via a secondary sale and arrived on the company's balance sheet as primary capital.
Upon receipt of the subscription amount, Granules India Limited will be in a net cash surplus position on a consolidated basis.
— Granules India company update to BSE, September 15, 2026
Follow the money
- 1
February 2026 — preferential issue raises funds
The September 11 filing states the company raised funds through a preferential issue in February 2026; the September 15 update references the company's disclosure dated February 23, 2026. India Ratings & Research acts as monitoring agency for the utilisation of proceeds.
- 2
Proceeds deployed ahead of schedule
Per the September 11 filing, the company deployed the February proceeds and executed the identified growth initiatives at a pace faster than originally envisaged — the funds were utilised significantly earlier than anticipated.
- 3
September 11 — promoter sells 1.72 crore shares
Dr. Krishna Prasad Chigurupati sold 1,72,00,000 shares via a block deal and the open market — ≈ ₹1,508.6 crore at the disclosed prices — with the filing stating the sale funds the second tranche of the preferential issue.
- 4
September 15 — balance ₹1,093 crore paid
Members of the promoter group paid the balance 75% subscription amount; 2,49,14,530 warrants are now fully paid and eligible for conversion. The company states it will be net cash surplus on a consolidated basis.
- 5
Next — conversion into equity
Conversion of the fully paid warrants into equity shares under the issue terms and applicable regulations. No conversion date is stated in the filings covered here.
Some arithmetic on the disclosed figures — computed, not disclosed. If ₹1,093 crore is exactly 75% of the total warrant consideration, the full subscription works out to about ₹1,457 crore, or roughly ₹585 per warrant for 2,49,14,530 warrants; the filings excerpted here do not state the per-warrant price directly. The seller's ≈ ₹1,508.6 crore of proceeds exceed the ₹1,093 crore balance payment by about ₹416 crore. On conversion, 2,49,14,530 new shares would be about 10.1% of the current 24.78 crore shares outstanding. And if all the warrants sit with promoter-group members, the group that held 38.02% (9.42 crore shares) as of June 30 would — after selling 1.72 crore shares and converting — hold about 10.19 crore shares on an expanded base of 27.27 crore, roughly 37.4%: a marginally lower percentage on a larger company, with a net increase of about 0.77 crore shares held.
Who bought the block
From exchange bulk/block-deal disclosures; identical bulk and block prints for the same client and quantity counted once. Values computed at the ₹872.50 print. Twelve further disclosed buyers took the remaining 24,49,840 shares.
The disclosed buys sum to exactly 1,32,95,129 shares — the same number as the block-sell leg, meaning the entire ₹872.50 block was absorbed by the twenty-two disclosed counterparties: foreign funds, domestic mutual funds, two insurers and a few individual investors. The second leg — 39,04,871 shares at ₹892.84 — has no disclosed buyers in the deal data, consistent with the filing's description of an open-market component. One detail worth noting: the company's filing names ChrysCapital and Allspring among the participants, but no entries under those names appear in the exchange's bulk/block disclosures for the day — their participation, if via the open-market leg or other vehicles, is not visible in this data.
A 17% three-month run, then a −4% session at the 52-week high
The stock ran from ₹778.40 on June 22 to ₹909.30 on September 11 — up about 16.8% over the sixty-session window, with the block prints crossing at ₹872.50, below that day's ₹909.30 close. September 11's 78.5 lakh shares was the heaviest volume of the window. Tuesday, September 15 — the first session after the sale intimation — was a study in two directions: the adjusted 52-week high of ₹922.95 was set intraday, yet the close at ₹872.60 was down 4.0%, back almost exactly to the block price. The close sits 5.5% below that high and 70.9% above the 52-week low of ₹510.55 (September 26, 2025).
The quarter behind the capital raise
Q3 FY26 consolidated figures are not in the dataset used for this report. Exceptional items: ₹−25.9 Cr in Q1 FY26, ₹15.9 Cr in Q4 FY26, ₹30.8 Cr in Q4 FY25.
Q1 FY27 consolidated revenue of ₹1,476.8 crore was up 22.0% over Q1 FY26's ₹1,210.1 crore, and net profit of ₹180.0 crore was up 59.8% over ₹112.6 crore — a comparison flattered somewhat by the ₹25.9 crore exceptional charge in the base quarter. Operating margin held near 23%. Consolidated interest cost was ₹21.1 crore in Q1 FY27, down from ₹32.7 crore in Q4 FY26 — a line worth tracking against the company's stated net-cash-surplus position, which the September 15 filing asserts but which the next balance-sheet disclosure will have to show.
The filings that would confirm or complicate this
Conversion
An allotment intimation converting the 2,49,14,530 fully paid warrants into equity, and the September 30 shareholding pattern — promoter holding stood at 38.02% as of June 30, before the sale and any conversion.
₹1,093 Cr deployment
The company says it will expedite the preferential issue objects; India Ratings' monitoring-agency report for the quarter ending September 30 will detail actual utilisation, as the July 21 report did for the first tranche.
Balance sheet
H1 FY27 disclosures showing whether the net cash surplus position on a consolidated basis appears in the numbers — consolidated interest cost was ₹21.1 Cr in Q1 FY27.
₹922.95
The adjusted 52-week high set intraday on September 15; the close at ₹872.60 sits 5.5% below it, and the September 15 evening filing had not yet traded within this report's price window.
The sequence is unusual mainly in how explicitly it is documented. Companies rarely state in a promoter-sale intimation what the proceeds are for; here the filing says the sale funds the second tranche of the preferential issue, and the balance payment landed four days later, to the rupee the filings describe: ₹1,093 crore in, 2,49,14,530 warrants fully paid. The market's first response to the sale intimation was a 4.0% decline — on a day that also printed the 52-week high — leaving the stock almost exactly at the block price.
What the filings assert but the numbers have not yet shown is the net cash surplus position and the accelerated deployment of the new tranche. Both are verifiable from scheduled disclosures — the monitoring-agency report and the half-year balance sheet — which makes this a story with checkpoints rather than a story requiring belief. The data suggests the near-term questions are mechanical: when the warrants convert, and what the ₹1,093 crore is spent on.
Informational and educational content only. Not investment advice.